Aggregated price index
Aggregated price index with volume information
- Medical Laboratories stocks up 0.6% on average while median return up 1.1% in a day
- Medical Laboratories stocks up 2.8% on average while median return up 5.5% in a week
- Medical Laboratories stocks up 22.7% on average while median return up 15.1% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
Click on + to show price series and click on ticker for stock detail page
* P/E and MarketCap are refreshed daily using IEX Cloud service. P/B, P/S, PEG, growth, short%, HelbyInstitute are refreshed weekly using Yahoo feeds. For latest stock stats please visit Yahoo Finance.
* Price Patter: / is upward trend, \ is downward trend, - is sideway. Click on the ticker to go to stock page to see Bayesian Trend model plot of the time series.
* Channel and change points are derived from Bayesian Trend model, where the channel slope is the growth rate while change points are those the model partition the time series.
- 1M winners are : Winners for past month are $NVTA 35.9%, $CDNA 35.0%, $GTH 33.9%, $PSNL 15.4%
- 1M losers are : Losers for past month are $CELC -17.9%
- 1W winners are : Winners for past week are $CDNA 11.0%, $VCYT 8.9%, $NTRA 7.7%, $WST 6.0%
- 1W losers are : Losers for past week are $CELC -3.6%
Index correlation analysis
Correlation for the past month is 28.4%, for the past 3 months is 17.3%
In the past month for a 5 days rolling window, the highest corrrelation is 48.4%, the lowest correlation is -9.3%, the latest correlation is 37.4%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 86.3% between CDNA and VCYT
The lowest correlation is -33.6% between ANPC and PSNL
CareDx, Inc ( NASDAQ:CDNA ) shareholders might be concerned after seeing the share price drop 24% in the last quarter...
BRISBANE, Calif., January 26, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Journal of the American College of Cardiology (JACC): Heart Failure has published a detailed guide1 to help clinicians transition from routine invasive endomyocardial biopsy (EMB) to a less invasive acute rejection monito
New York, NY, Jan. 20, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (the “Company”) (Nasdaq: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection announced that, on January 13, 2023, it received a Staff determination letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company of the Staff’s determination to delist the Company’s securities f
Cancer test business Personalis Inc. is cutting a third of its staff in a move that's estimated to affect more than 100 workers. It said the layoffs are being done to "reduce operating costs and improve operating efficiency." Personalis didn't specify the number of jobs to be cut but in an annual report last year it said it employed 326 people at the end of 2021.
Personalis Inc (NASDAQ: PSNL) approved a reduction in the company's workforce by up to approximately 30% to reduce operating costs and improve operating efficiency. The reduction in workforce is expected to be completed on March 20, 2023. The company estimates that it will incur charges of approximately $3 million for severance payments and employee benefits, primarily in the first quarter of 2023. The company estimates that the reduction in workforce will save approximately $17 million, net in
Raymond James upgraded Natera Inc (NASDAQ: NTRA) to Outperform from Market Perform and a price target of $58 on a catalyst-rich setup for 2023 across segments, but most interestingly, in the molecular residual disease arena. The analyst expects additional coverage and potential guideline inclusion, at least for colorectal cancer, with women's health having its catalysts. The analyst also upgraded Myriad Genetics Inc (NASDAQ: MYGN) to Outperform from Market Perform and a price target of $25. Raym
BEIJING, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that the Company had received a notification letter (“Compliance Notice”) from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), dated Jan
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
BRISBANE, Calif., January 11, 2023--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced its leading participation and top spot, for the fourth consecutive year, as a Distinguished Founder’s Circle Sponsor for the 23rd Annual ASTS (American Society of Transplant Surgeons) State of the Art Winter Symposium
BRISBANE, Calif., January 09, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported preliminary financial results for the fourth quarter and full year ended December 31, 2022.